We are live on ! Find out more
IMNP

Immune Pharmaceuticals Inc.
IMNP

Delisted

IMNP was delisted on the 25th of July, 2018.

Back to rankings

15 hedge funds and large institutions have $483K invested in Immune Pharmaceuticals Inc. in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 15 → 15 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

37% less capital invested

Capital invested by funds: $768K → $483K (-$285K)

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$77.7K
2
BFA
BlackRock Fund Advisors
California
+$76.9K
3
LPL Financial
LPL Financial
California
+$42K
4
Goldman Sachs
Goldman Sachs
New York
+$4.2K
5
Morgan Stanley
Morgan Stanley
New York
+$63

Top Sellers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
-$34.3K
2
Nomura Holdings
Nomura Holdings
Japan
-$27K
3
TSS
Two Sigma Securities
New York
-$18K
4
BPCE
Bank Pictet & Cie (Europe)
Germany
-$15K
5
IFS
Ifrah Financial Services
Arkansas
-$7.31K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Sio Capital Management
New York
$144K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$102K +$77.7K +3,698 +112%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$73K – – –
BFA
4
BlackRock Fund Advisors
California
$54K +$76.9K +3,659 New
LPL Financial
5
LPL Financial
California
$32K +$42K +2,000 New
EEG
6
E.E. Geduld
$26K – – –
Goldman Sachs
7
Goldman Sachs
New York
$25K +$4.2K +200 +13%
IFS
8
Ifrah Financial Services
Arkansas
$11K -$7.31K -348 -32%
VKH
9
Virtu KCG Holdings
New York
$8K -$34.3K -1,631 -76%
PRCM
10
Pine River Capital Management
Minnesota
$4K – – –
BIM
11
BlackRock Investment Management
Delaware
$2K – – –
UBS Group
12
UBS Group
Switzerland
$1K -$6.43K -306 -85%
LTFS
13
Ladenburg Thalmann Financial Services
Florida
$1K – – –
Nomura Holdings
14
Nomura Holdings
Japan
– -$27K -1,160 Closed
TSS
15
Two Sigma Securities
New York
– -$18K -774 Closed
BPCE
16
Bank Pictet & Cie (Europe)
Germany
– -$15K -645 Closed
BIT
17
BlackRock Institutional Trust
California
– -$5K -197 Closed
Morgan Stanley
18
Morgan Stanley
New York
– +$63 +3 New
TRCT
19
Tower Research Capital (TRC)
New York
– +$63 +3 New

IMNP Hedge Fund Activity: Q4 2015 in Review

15 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q4 2015, worth a combined $483K — down 37% from $768K a quarter earlier.

Fund positioning in IMNP was balanced in Q4 2015: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, adding an estimated $77.7K. The largest seller was Virtu KCG Holdings, cutting an estimated $34.3K.

  • 15 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q4 2015, unchanged from Q3 2015.
  • Funds reported $483K of Immune Pharmaceuticals Inc. stock for Q4 2015, down 37% quarter-over-quarter.
  • 4 funds opened new Immune Pharmaceuticals Inc. positions in Q4 2015 and 4 closed out, a net change of 0 holders.
  • The largest Immune Pharmaceuticals Inc. buyer in Q4 2015 was Vanguard Group, an estimated $77.7K added.
  • The largest Immune Pharmaceuticals Inc. seller in Q4 2015 was Virtu KCG Holdings, an estimated $34.3K sold.

Based on aggregated 13F filings for Q4 2015.